Filing Details
- Accession Number:
- 0001209191-21-055206
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-08 18:42:53
- Reporting Period:
- 2021-09-03
- Accepted Time:
- 2021-09-08 18:42:53
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178879 | Amicus Therapeutics Inc. | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1743122 | Samantha Prout | C/O Amicus Therapeutics, Inc. 3675 Market Street Philadelphia PA 19104 | Principal Accounting Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-09-03 | 1,980 | $10.04 | 85,150 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2021-09-03 | 2,945 | $9.55 | 88,095 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-09-03 | 4,925 | $12.01 | 83,170 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (right to buy) | Disposition | 2021-09-03 | 1,980 | $0.00 | 1,980 | $10.04 |
| Common Stock | Stock Options (right to buy) | Disposition | 2021-09-03 | 2,945 | $0.00 | 2,945 | $9.55 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 3,168 | 2029-01-02 | No | 4 | M | Direct | |
| 12,182 | 2030-01-02 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.00 to $12.0650 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- As of September 3, 2021, 1,980 options were fully vested and exercisable and 3,168 remained unvested from this grant.
- As of September 3, 2021, 6,301 options were fully vested and exercisable and 8,826 remained unvested from this grant.
Billionaire Hedge Funds
